7-Eleven, Inc.'s Laredo Taco Company Launches New Flavor-Packed Chicken Fajita Burrito
Customers can also enjoy meal deals from Raise the Roost and Speedy Café starting at $4
IRVING, Texas, Feb. 10, 2025 /PRNewswire/ -- New crave-worthy menu items and meal deals are here! Today, 7-Eleven, Inc.'s Laredo Taco Company® restaurant launched an all-new Chicken Fajita Burrito that's sure to satisfy every craving. Plus, customers can start their day with Raise the Roost® and Speedy Café® crave-worthy breakfast offerings or enjoy delicious lunch deals at participating 7-Eleven®, Speedway® and Stripes® stores nationwide.
The bold new Chicken Fajita Burrito at Laredo Taco Company features perfectly seasoned chicken, onions and peppers grilled to perfection, wrapped in a fresh tortilla. Pair it with a refreshing Big Gulp® drink to complete the meal. Additionally, 7Rewards® and Speedy Rewards® members can enjoy an exclusive $4 meal deal that includes a Chorizo Breakfast Taco and any 8.4oz Red Bull to jumpstart the day.* Known for its authentic hot-off-the-grill flour tortillas made fresh daily, Laredo Taco Company brings the heat and the satisfaction with a salsa bar including a wide selection of salsas and pico de gallo.
Customers can also stop by Raise the Roost and Speedy Café restaurants for a $4 meal deal, including a delicious Croissant Breakfast Sandwich and a 8.4 oz Red Bull – the perfect breakfast or brunch option.**
'With the start of a new year, we are offering fresh and flavorful menu items across Laredo Taco Company, Raise the Roost and Speedy Café,' said William Armstrong, Senior Vice President, Restaurants at 7-Eleven, Inc. 'From the sizzling Chicken Fajita Burrito at Laredo Taco Company to exclusive breakfast deals for our rewards members, we're committed to providing our customers with delicious, convenient meals at unbeatable prices.'
Find even more savings on unbeatable deals at participating 7-Eleven, Speedway and Stripes stores nationwide:
$5 Pizza Slice Meal Deal: Now until March 4, 7Rewards and Speedy Rewards members can get 2 slices of any flavor pizza and a 20-ounce Coca-Cola for just $5.***
2 for $3 Value Grill Items: Savor any 2 grill favorites like Rollers, Taquitos and Egg Rolls for just $3! Craving more? Loyalty members can make any snack or meal even better by getting 3 grill items for $4.****
Bone-In & Boneless Wings: Loyalty members can snag 5 bone-in wings for $5.99 or go boneless with 8 wings for just $3.99 — saving never tasted so good.*****
Become a loyalty member by downloading the 7-Eleven or Speedway apps from the App Store or Google Play or by visiting 7Rewards.com or SpeedyRewards.com.
*Valid from 1/08/25 thru 3/4/25. See app for more details. ©2025 7-Eleven, Inc. All rights reserved.
**Valid thru 12/31/25. Plus tax. Participating U.S. Stores. See app for full terms. 2025 7-Eleven, Inc. All rights reserved. Exclusive to loyalty members only.
***Valid 1/8/25-3/4/25. Plus tax. Limit 2 per day. See app for more details. ©2025 7-Eleven, Inc. All rights reserved.
**** and ***** Valid 1/8/25 – 1/6/26. Plus Tax. See app for more details. ©2025 7-Eleven, Inc. All rights reserved.
About 7-Eleven, Inc.
7-Eleven, Inc. is the premier name in the U.S. convenience-retailing industry. Based in Irving, Texas, 7-Eleven operates, franchises and/or licenses more than 13,000 stores in the U.S. and Canada. In addition to 7-Eleven® stores, 7-Eleven, Inc. operates and franchises Speedway®, Stripes®, Laredo Taco Company® and Raise the Roost® Chicken and Biscuits locations. Known for its iconic brands such as Slurpee®, Big Bite® and Big Gulp®, 7-Eleven has expanded into high-quality sandwiches, salads, side dishes, cut fruit and protein boxes, as well as pizza, chicken wings and mini beef tacos. 7-Eleven offers customers industry-leading private brand products at outstanding value. Customers can earn and redeem points on various items in stores nationwide through its 7Rewards® and Speedy Rewards® loyalty programs with more than 80 million members, place an order in the 7NOW® delivery app in over 95% of the convenience retailer's footprint, or rely on 7-Eleven for other convenient services. Find out more online at www.7-eleven.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Red Bull agree deal to buy Newcastle Falcons and keep Premiership club afloat
Brett Connon of Newcastle Falcons in action against Leicester Tigers during a Premiership match in May. Brett Connon of Newcastle Falcons in action against Leicester Tigers during a Premiership match in May. Photograph:Red Bull has agreed a deal to buy Newcastle Falcons which includes a commitment to keep the club in the city and will ensure the Premiership remains a 10-team competition next season. Newcastle have been for sale for over a year, with owner Semore Kurdi no longer willing to fund multimillion-pound annual losses, leading to fears they could become the fourth Premiership club to go bust in the last two years after Wasps, Worcester and London Irish. Advertisement Related: An ugly pack and backs worth paying to watch: Bath have taken us back to the 1990s | Andy Bull Such has been the concern for Newcastle's future that the other Premiership clubs agreed in principle to provide a £4m loan to enable them to take part in the competition next season, with a nine-team top-flight not thought to be commercially viable. Red Bull is understood to have reach an agreement to take over the cash-strapped club however, and take on their £39m debts. These include £14.5m in unpaid treasury loans taken out during the Covid-19 pandemic. During negotiations with the Austrian energy drinks company the prospect of moving the club to the 26,000-capacity Darlington Arena 40 miles away was discussed, but the Guardian has been told that Red Bull's takeover plan involves Newcastle staying at Kingston Park, which has been their home for the past 35 years. Advertisement Red Bull's decision to stay in Newcastle is likely to be popular with the club's longsuffering fans, who did not see them win a single match last season and only two this as Steve Diamond's side finished bottom of the Premiership on both occasions. The company's vision for the club is understood to be based on using their brands and marketing expertise to gain support from younger people in the city, with several campaigns planned to appeal to Newcastle's student population. Given the company's footballing connections Red Bull is also expected to seek a close working relationship with Newcastle United. The club's outgoing sporting director Paul Mitchell previously worked at RB Leipzig. Newcastle will be Red Bull's first rugby purchase, but the club aligns with it's purchase model of snapping up underperforming sports teams with a business plan of transforming them into global brands. The company paid Ford just $1 to buy the failing Formula One team, Jaguar Racing, in 2004 and have successfully transformed them into giants of the sport, with Red Bull Racing winning eight world drivers' championships and six constructors' titles in the last 15 years. In addition to football clubs, RB Leipzig, Red Bull Salzburg and the New York Red Bulls, they also own 9.9% of Leeds United and are heavily involved in motor sport and winter sports. Advertisement Attracting a new owner such as Red Bull is also a coup for Premiership Rugby, who are seeing much-needed signs of growth for the sport. Viewing figures for Premiership matches on TNT Sport are up 10% on last season before Saturday's final between Bath and Leicester, with the increase 47% when the game directly follows a Premier League match. In another significant boost TNT Sport last month agreed a new five-year deal giving it exclusive live rights for every Premiership match until 2031. Red Bull and Newcastle declined to comment on the deal.
Business Upturn
3 hours ago
- Business Upturn
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
By GlobeNewswire Published on June 13, 2025, 11:30 IST Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of: BIO International Convention 2025 , on June 16, in Boston, US; , on June 16, in Boston, US; Portzamparc – 2025 Mid&Small Caps Conference (hosted by BNP Paribas Group ), on June 18, in Paris, France; (hosted by ), on June 18, in Paris, France; International Neoantigen Summit , on June 24, 2025, in Amsterdam, Netherlands; , on June 24, 2025, in Amsterdam, Netherlands; International Academy of Oral Oncology 2025 (IAOO), on July 18, in Liverpool, UK. Following the positive clinical data on our individualized neoantigen cancer vaccine TG4050, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here), Transgene together with Prof. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology), have discussed the data presented, the unmet medical need and current treatment landscape for patients suffering from head and neck cancers in a virtual event available on Transgene website and here. *** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC. With its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Additional information about Transgene is available at: Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene Contacts Disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250613_Transgene_Upcoming_Events_EN Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
3 hours ago
- Yahoo
Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pharmacist delivering a specific medication to a patient in a specialty pharmacy. A pooled research found that sweat chloride (SwCl) levels below 60 mmol/L were associated with improved lung function, fewer exacerbations, and better nutritional and quality of life outcomes. Even larger numerical improvements were observed for SwCl below 30 mmol/L. According to post hoc data from Phase 3 trials, ALYFTREK outperformed TRIKAFTA® in terms of health outcomes for adults, adolescents, and children aged 6 to 11. Approximately 109,000 people worldwide, 94,000 of whom live in North America, Europe, and Australia, have cystic fibrosis. The majority of patients have at least one F508del mutation, which is the result of mutations in the CFTR gene. TRIKAFTA® is being donated in 14 lower-income countries, and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) medications currently serve over 75,000 people in 60+ countries, or almost two-thirds of eligible patients. It is among the stocks with the biggest upside. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
